Open AccessTherapeutic effect of α‐galactosylceramide‐loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells
Author(s) -
Matsuyoshi Hidetake,
Hirata Shinya,
Yoshitake Yoshihiro,
Motomura Yutaka,
Fukuma Daiki,
Kurisaki Akari,
Nakatsura Tetsuya,
Nishimura Yasuharu,
Senju Satoru
Publication year - 2005
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2005.00123.x
Subject(s) - antigen , biology , antigen presenting cell , immunology , cross presentation , dendritic cell , natural killer t cell , chemokine , cancer research , microbiology and biotechnology , cd8 , t cell , immune system
The close cooperation of both innate and acquired immunity is essential for the induction of truly effective antitumor immunity. We tested a strategy to enhance the cross‐talk between NKT cells and conventional antigen‐specific T cells with the use of αGalCer‐loaded dendritic cells genetically engineered to express antigen plus chemokine, attracting both conventional T cells and NKT cells. DC genetically engineered to express a model antigen, OVA, along with SLC/CCL21 or monokine induced by IFN‐γ/CXCL9, had been generated using a method based on in vitro differentiation of DC from mouse ES cells. The ES‐DC were loaded with α‐GalCer and transferred to mice bearing MO4, an OVA‐expressing melanoma, and their capacity to evoke antitumor immunity was evaluated. In vivo transfer of either OVA‐expressing ES‐DC, stimulating OVA‐reactive T cells, or α‐GalCer‐loaded non‐transfectant ES‐DC, stimulating NKT cells, elicited a significant but limited degree of protection against the i.p. disseminated MO4. A more potent antitumor effect was observed when α‐GalCer was loaded to ES‐DC expressing OVA before in vivo transfer, and the effect was abrogated by the administration of anti‐CD8, anti‐NK1.1 or anti‐asialo GM1 antibody. α‐GalCer‐loaded double transfectant ES‐DC expressing SLC along with OVA induced the most potent antitumor immunity. Thus, α‐GalCer‐loaded ES‐DC expressing tumor‐associated antigen along with SLC can stimulate multiple subsets of effector cells to induce a potent therapeutic effect against peritoneally disseminated tumor cells. The present study suggests a novel way to use α‐GalCer in immunotherapy for peritoneally disseminated cancer. ( Cancer Sci 2005; 96: 889–896)